Sushen Medicamentos Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 03-07-2024
- Paid Up Capital ₹ 9.60 M
as on 03-07-2024
- Company Age 23 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.96 Cr
as on 03-07-2024
- Satisfied Charges ₹ 1.99 Cr
as on 03-07-2024
- Revenue 4.77%
(FY 2023)
- Profit 176.33%
(FY 2023)
- Ebitda 73.80%
(FY 2023)
- Net Worth -6.60%
(FY 2023)
- Total Assets -1.13%
(FY 2023)
About Sushen Medicamentos
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 9.60 M.
The company currently has active open charges totaling ₹9.96 Cr. The company has closed loans amounting to ₹1.99 Cr, as per Ministry of Corporate Affairs (MCA) records.
Aman Kulabkar and Kaushik Shah serve as directors at the Company.
- CIN/LLPIN
U24231GJ2001PTC040113
- Company No.
040113
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Oct 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sushen Medicamentos?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kaushik Shah  | Managing Director | 01-Jul-2003 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Aman Kulabkar | Director | 01-May-2021 | Current |
Financial Performance of Sushen Medicamentos.
Sushen Medicamentos Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.77% increase. The company also saw a substantial improvement in profitability, with a 176.33% increase in profit. The company's net worth dipped by a decrease of 6.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sushen Medicamentos?
In 2023, Sushen Medicamentos had a promoter holding of 97.92% and a public holding of 2.08%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 29 Dec 2012 | ₹9.96 Cr | Open |
Axis Bank Limited Creation Date: 23 Mar 2018 | ₹2.47 M | Satisfied |
Others Creation Date: 27 Apr 2016 | ₹1.55 M | Satisfied |
How Many Employees Work at Sushen Medicamentos?
Sushen Medicamentos has a workforce of 39 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sushen Medicamentos, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sushen Medicamentos's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
